News News Today | Latest News Updates

Pyrotech Therapeutics Doses First Subject in Phase 1 Study of PTT-121, the World's First Selective GSDMD Inhibitor to Enter Clinical Development

Clinical milestone validates the company's platform for drugging "undruggable" targets BEIJING, Sept. 1, 2026 /PRNewswire/ -- Pyrotech Therapeutics ("Pyrotech" or the "Company"), a clinical-stage biopharmaceutical company pioneering innate immune modulation and pyroptosis-targeted...

Pyrotech Therapeutics Doses First Subject in Phase 1 Study of PTT-121, the World's First Selective GSDMD Inhibitor to Enter Clinical Development

In This Category

Get in Touch

Latest Post

Quick Links

Newsletter